Paolo Tarantino: We review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer

Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, posted on LinkedIn:

“In our latest article, just published on ESMO Open, we review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer.

Thanks to AstraZeneca for supporting this publication and to H. Earle for bravely sharing with us and the journal readers her personal experience while receiving treatment with T-DXd.

See link here.”

Source: Paolo Tarantino/LinkedIn